This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

May 15, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement of the results of joint research with RaQualia Pharma Inc.

We are pleased to announce that we have obtained favourable results from the joint research being conducted with RaQualia Pharma Inc. (Head Office: Nagoya City, Aichi Prefecture; Representative Director: Masaki Sudo), aimed at discovering new drug candidates for the treatment of eye diseases. Details of the research results are provided in the attached document.

This matter will have no impact on the earnings forecast for the fiscal year ending December 2025. However, we believe it will contribute to the medium−to long-term expansion of our ophthalmology pipeline.

End

NEWS RELEASE

May 15, 2025
D.Western Therapeutics Institute, Inc.
RaQualia Pharma Inc.

To all members of the press

Results of joint research between D.Western Therapeutics Institute, Inc. and RaQualia Pharma Inc.

D.Western Therapeutics Institute, Inc. (Head Office: Nagoya City, Aichi Prefecture; President and CEO: Yuki Hidaka; hereinafter referred to as “DWTI”) and RaQualia Pharma Inc. (Head Office: Nagoya City, Aichi Prefecture; Representative Director: Masaki Sudo; hereinafter referred to as “RaQualia Pharma”) are pleased to announce that they have achieved positive results in their joint research (hereinafter referred to as “the Joint Research”) aimed at developing a new drug for the treatment of eye diseases.

This Joint Research project began in December 2022. RaQualia Pharma is responsible for synthesizing a group of compounds targeting specific ion channels (hereinafter referred to as “the compounds”) utilizing its ion channel drug discovery technology, while DWTI is verifying the potential of the compounds as treatments for eye diseases through pharmacodynamic tests, leveraging its evaluation technology in the ophthalmic field. As a result, favorable pharmacological effects were confirmed in animal models of retinal diseases. The Joint Research is currently ongoing, and based on these results, further verification will be conducted to explore the possibility of collaboration in the next phase.
DWTI and RaQualia Pharma will continue to conduct research and development with the aim of delivering innovative new drugs to patients by combining the core technologies of both companies. In addition, the technical results and intellectual property rights obtained through this Joint Research are shared by both parties.

DWTI and RaQualia Pharma will utilize the results of this Joint Research to create new development candidates.

【About D.Western Therapeutics Institute】
D.Western Therapeutics Institute is a biotech company with the mission of “Innovative New Drugs to the World from Japan,” aiming to provide patients with more effective medicines as quickly as possible. DWTI specialize in the creation of kinase inhibitors (low molecular weight compounds) and have own proprietary drugs on the market. Currently, focusing on the ophthalmic field and are working on regenerative medicine products to contribute to providing the best possible treatment for patients.
For more details, please visit DWTI's website at https://www.dwti.co.jp

【About RaQualia Pharma】

RaQualia Pharma is a research and development-oriented venture company headquartered in Nagoya City, with a research facility also located there. The company aims to be a “global drug discovery innovator” that develops pharmaceuticals that meet the needs of the medical field. By leveraging cutting-edge life science technologies, RaQualia Pharma creates innovative new drug candidates through its unique open innovation approach and is committed to delivering truly valuable new treatments to patients.

For more details, please visit RaQualia Pharma's website at https://www.raqualia.com.

Contact for inquiries regarding this matter

D.Western Therapeutics Institute, Inc.	RaQualia Pharma Inc.
Business Management Department	Business Administration department
TELL：052-218-8785 (Main number)	TELL：052-446-6100 (Main number)
E-mail：info@dwti.co.jp	E-mail：ask@raqualia.com